Lab Notes: Context identifies lead cancer drug candidate; Aclaris inks licensing deal worth up to $96M
This week's Philadelphia-area life sciences industry update includes a women's oncology company identifying a lead product candidate, a biopharmaceutical company's multimillion-dollar licensing deal, a biotech firm initiating human clinical trials, and more.
Here's the roundup:
The Philadelphia-based women's oncology company selected CTIM-76 as its lead clinical development candidate targeting Claudin 6 (CLDN6) positive cancers.
CLDN6-enriched cancers include ovarian, endometrial, testicular, …
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Endometrial Cancer | Health Management | Ovarian Cancer | Ovaries | Pharmaceuticals | Women